Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers. [electronic resource]
Producer: 20131028Description: 82 p. digitalISSN:- 1471-2377
- 2',5'-Oligoadenylate Synthetase -- metabolism
- Body Mass Index
- Female
- Follow-Up Studies
- Humans
- Immunologic Factors -- adverse effects
- Interferon-beta -- adverse effects
- Kaplan-Meier Estimate
- Male
- Multiple Sclerosis, Chronic Progressive -- drug therapy
- Neopterin -- metabolism
- Predictive Value of Tests
- Retrospective Studies
- Treatment Outcome
- beta 2-Microglobulin -- metabolism
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.